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Background: Estrogen receptor (ER) β acts as a tumor suppressor in malignant mesotheliomas.
Methods: Here we explored the anti-proliferative and anti-tumorigenic efficacy of the selective ERβ agonist,
KB9520, in human mesothelioma cell lines in vitro and in a mesothelioma mouse model in vivo.
Results: KB9520 showed significant anti-proliferative effect in ERβ positive human malignant pleural mesothelioma
cells in vitro. Selective activation of ERβ with KB9520 sensitized the cells to treatment with cisplatin, resulting in
enhanced growth inhibition and increased apoptosis. Furthermore, in CD1 nude mice mesothelioma tumor growth
was significantly inhibited when KB9520 was added on top of the standard of care chemo combination cisplatin/
pemetrexed, as compared to the cisplatin/pemetrexed alone group. Importantly, KB9520 exerted a protective effect
to cisplatin toxicity in the non-malignant mesothelium derived MET5A cells.
Conclusions: Together, the data presented suggest that selective targeting of ERβ may be an efficacious
stand-alone treatment option and/or become an important add-on to existing malignant mesothelioma therapy.
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Malignant pleural mesothelioma (MPM) is an aggressive
cancer associated with exposure to asbestos. Currently
rates of MPM are rising and estimates indicate that the
incidence of MPM will peak within the next 10–15 years
in the western world, while in Japan the peak is predicted
not to occur until 40 years from now [1,2]. Although the
use of asbestos has been banned in many countries
around the world, production of and the potentially haz-
ardous exposure to asbestos is still present with locally
high incidences of mesothelioma [3]. Today a new man-
made material, carbon nanotubes (CNTs), has arisen as a
concern; CNTs may display ‘asbestos-like’ pathogenicity
with mesothelioma induction potential [4,5]. The pharma-
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unless otherwise stated.and tissue accumulation, is therefore intensely investi-
gated; “it is better to be safe than sorry” [6].
MPM is an extremely difficult disease to treat, with a
median overall survival ranging between 9 and 17 months,
regardless of disease stage [7,8]. The combination of
pemetrexed and cisplatin has been established as the
current standard of care (SOC) but only 40% of treated
patients show response to this therapy, with an overall
median survival of 12.1 months [9].
There is an urgent need for new targeted therapy for
clinical management of MPM that can stop progression
and stabilize the disease or ideally erase the tumor, ei-
ther as add-on to SOC, to improve treatment efficacy
and reduce chemoresistance and toxicity, or as mono-
therapy for patients whose performance status does not
allow aggressive treatment.
Rapid advances in the understanding of cancer biology
are leading to identification of new targets for cancer
treatment and personalized therapy is rapidly becomingLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of life for cancer patients [10-12].
The expression of estrogen receptor beta (ERβ) in ma-
lignant pleural and peritoneal mesothelioma correlates
with longer patient survival and is an independent prog-
nostic factor [13,14]. Our group recently demonstrated
that 70-80% of MPMs express ERβ, which acts as a tumor
suppressor, inhibiting MPM cell proliferation and inva-
siveness [13,15].
ERβ is the second ER subtype identified in several human
tissues traditionally believed to be ER negative [16]. ERβ is
expressed and demonstrated to exert anti-proliferative
effects in different preclinical in vitro and in vivo models
of human cancers, for example, breast, colon, prostate,
lymphoma, and pleural mesothelioma [13,15,17-25]. More-
over, ERβ is proposed to mediate the beneficial clinical
effects in ERα negative breast cancer patients [26], in
malignant intraperitoneal mesothelioma [27], and in the
prevention of colon cancer in women on menopausal
hormone therapy (MHT) [28].
Drugs that selectively target ERβ might be safer than
non-selective estrogens, which are associated with in-
creased risk of breast, endometrial and ovarian cancer in
women and the development of prostate cancer in men.
These serious side effects of non-selective estrogens are
mediated by the ERα subtype [29-32]. Several synthetic
and natural ERβ-selective compounds have been identified
[19,33-36] that have shown promising anti-tumorigenic
efficacy in preclinical cancer models [37-43]. Therefore,
drugs with selectivity for ERβ might prove promising in
the the development of novel, targeted therapies for the
clinical management of human cancers.
In the present study, we characterized the efficacy of
KB9520, a selective ERβ agonist, to inhibit MPM cell
growth in vitro and in vivo. Moreover, we investigated
the possibility of an additive or synergistic effect between
KB9520 and the SOC regimen (cisplatin/pemetrexed) for
treatment of MPM.
Results
KB9520-mediated ERβ activation affects MPM cell
proliferation
The growth inhibitory effect of different concentrations
of KB9520 (range 1–100 nM) was tested on ERβ posi-
tive REN mesothelioma cells (Figure 1A). KB9520 sig-
nificantly (p ≤ 0,05) reduced cell growth and viability in
a concentration-dependent manner, with highest effi-
cacy at 10 nM. For comparison we also examined the
concentration-dependent growth inhibitory effect of
17β-estradiol (E2) on REN cells (Figure 1B). The anti-
proliferative activity of KB9520 as single agent was then
assessed in the non-malignant mesothelium derived
MET5A cells and in the malignant mesothelioma REN,
MMB, H2596, and MSTO-211H cell lines, respectively(Figure 1B). KB9520 significantly (p ≤ 0,05) inhibited
proliferation of the REN and MMB cells, whereas no
inhibitory effect was observed in the MET5A cells, des-
pite high endogenous levels of ERβ. The H2596 cells
express very low levels of ERβ which explains their weaker
response to KB9520. As expected, the ERβ negative
MSTO-211H cells and the ERβ silenced REN and MMB
cells showed no response to KB9520 treatment. However,
transient transfection of the MSTO-211H cells with an
ERβ expression vector sensitized also these cells to
KB9520 (Figure 1B). In addition, increasing the expression
of ERβ in H2596 by transient transfection with an ERβ ex-
pression vector increased the response to KB9520 also in
these cells (data not shown).
KB9520 significantly increases the effect of cisplatin/
pemetrexed in vitro and in vivo
To test if KB9520 influences MPM cell response to
chemotherapy in vitro, we explored the effect of adding
10 nM KB9520 to the cisplatin/pemetrexed chemo com-
bination (at their respective IC50 concentrations) on REN
cell viability. As shown in Figure 2A, the triple combin-
ation KB9520/cisplatin/pemetrexed (10 nM/100 μM/
22 μM, respectively) was superior (p ≤ 0.05) to either
KB9520 or cisplatin/pemetrexed treatment alone.
To confirm the role of agonist activated ERβ in the en-
hanced response to chemotherapy, the effect of KB9520
on top of the cisplatin/pemetrexed combination was eval-
uated also in the mesothelioma in vivo mouse model.
Six weeks old CD1 nude male mice were inoculated
intra peritoneum with 2×106 REN cells (4 groups, 10
animals per group). Prior to inoculation, the MPM cells
were transduced with a lentiviral vector carrying the lu-
ciferase gene, to allow imaging in live mice. Treatment
of the animals was initiated fifteen days after cell inocu-
lation when tumor take-rate in the peritoneal cavity was
100% in all animal groups. The ERβ-selective agonist
KB9520 was administrated on day 15 through 35 by
subcutaneous injection at 10 mg/kg/day. Untreated ani-
mals were subcutaneously dosed with empty vehicle.
Two groups were treated at day 18 and 25 with 5 mg/kg
cisplatin followed by 5 days treatment with 150 mg/kg
pemetrexed (days 19–23 and 26–30), alone or in com-
bination with KB9520 (see the treatment schedule in
Table 1). KB9520 alone treated mice produced a similar
decrease in tumor dimensions as the cisplatin/peme-
trexed treated group compared to vehicle controls at
day 10 (data not shown). After 21 days of treatment, we
observed a statistically significant reduction in tumor
growth in the group treated with KB9520 plus cisplatin/
pemetrexed as compared to the vehicle, KB9520, and
cisplatin/pemetrexed groups, respectively (Figure 2B, C).
Furthermore, these statistical significant differences were
confirmed when the tumor growth curves were compared.
Figure 1 KB9520 mediated ERβ activation affects MPM cells proliferation. A) Bar graph shows the percentage of growth inhibition of REN
cells after 24 hours treatment with different concentrations of KB9520 (range 1–100 nM) versus untreated cells. B) Bar graph shows the percentage of
growth inhibition of REN cells after 24 and 72 hours treatment with different concentrations of 17β-estradiol (range 1–100 nM) versus untreated cells.
C) Bar graph shows the percentage of growth inhibitory effect of 10 nM KB9520 at 24 and 48 hours in mesothelium derived cells (MET5A),
mesothelioma cells with different levels of endogenous ERβ expression (REN, MMB, H2596 and MSTO-211H), ERβ silenced REN and MMB cells
(REN/siRNA ERβ, MMB/siRNA ERβ) and MSTO-211H/ERβ cells, which were transiently transfected to express human ERβ. Western blots, below
the bar graph, show ERβ protein expression for each cell line. Tubulin was included as a loading control. Each graph is representative of three
independent experiments. Each bar represents mean ± s.d. *p ≤ 0.05.
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Figure 2 KB9520 significantly increases cisplatin/pemetrexed effects in vitro and in vivo. A) Percentage of viable REN cells exposed for
24 hours to 10 nM KB9520 alone or in combination with cisplatin (100 μM) and pemetrexed (22 μM), versus untreated cells. Graph is
representative of three independent experiments. Each bar represents mean ± s.d. *p ≤ 0.05. B) and C) Box plots of the 4 different treatment
groups (10 mice/group) showing in vivo mean tumor growth (B) and mean tumor growth inhibition (C) evaluated after 21 days of treatment.
The thick segments represent the medians while the upper and lower borders of each rectangle represent the quartiles. Bars show minimum and
maximum values for each group, outliers are identified by a small circle. Kruskal-Wallis rank sum test (in B) confirms that combination treatment
significantly reduced tumor growth, compared with control or single treatments.
Table 1 Treatment schedule of the in vivo experiment
Day 1 Treatment Day 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 Day 35
REN cells injected
KB9520 (10 mg/kg) X X X X X X X X X X X X X X X X X X X X X
cisplatin (5 mg/kg) X X
pemetrexed (150 mg/kg) X X X X X X X X X X
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monitoring changes of mice body weights during drug ad-
ministration (data not shown). 35 days after MPM cell in-
oculation all animals were sacrificed and tumors were
dissected and immediately frozen.
Biological sustainability of KB9520
Since the in vivo plasma half-life of KB9520 is only ap-
proximately 1 hour in mice (data not shown) we decided
to investigate the biological sustainability and mechan-
ism of action of KB9520 in vitro to better understand its
anti-tumorigenic activity and synergism with cisplatin/
pemetrexed in vivo. Firstly, we tested the anti-proliferative
response to brief exposures (1, 2, 4, 8, 16 and 24 hours) to
10 nM KB9520 on the ERβ positive REN cells (Figure 3A).
An exposure of 2 hours presented significantly (p ≤ 0.05)
increased inhibitory activity relative to 1 hour exposure
and exposures longer than 8 hours. Successively, the
2 hours exposure to KB9520 was characterized further.Figure 3 Biological sustainability of KB9520. A) Percentage of growth i
with 10 nM KB9520 followed by wash-off and continued growth in normal
pre-exposed for 2 hours to normal medium or 0.4, 2, 10 nM KB9520 follow
72 hours in normal medium, respectively. Each graph is representative of threCells were treated with different concentrations of
KB9520 (0.4, 2 and 10 nM) for 2 hours followed by
wash-off and continued growth in normal medium
(without KB9520) for an additional 24, 48 and 72 hours
(Figure 3B). Control cultures were maintained in normal
medium only. The duration of inhibitory effect on REN
cell proliferation sustained for at least 24 hours irre-
spective of concentration of KB9520 used in the 2-hours
pre-treatment period. The largest anti-proliferative ef-
fect was, however, observed with the highest KB9520
concentration used. After 24 hours the cells slowly
regained proliferative activity and from ~48 hours post
KB9520 pre-treatment, their proliferative rates were simi-
lar to that of REN cells cultivated in normal medium from
start of study.
KB9520 pre-treatment sensitizes REN cells to cisplatin
To explore the sequence of drug administration and its
effect on cell proliferation we performed add-on ornhibition in REN cells after 1, 2, 4, 8, 16 or 24 hours pre-treatment
medium for an additional 24 hours. B) Mean number of REN cells
ed by wash-off and continued growth for additional 24-, 48- and
e independent experiments. Each point represents mean ± s.d. *p≤ 0.05.
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100 μM cisplatin was added to REN cell cultures pre-
treated for 2, 4, 8 and 12 hours with 10 nM KB9520
(Figure 4A). The enhanced anti-proliferative effect of
cisplatin was time-dependent with the greatest inhibi-
tory effect obtained adding cisplatin within 2 hours of
KB9520 pre-treatment.
The reverse order of pre-treatment starting with cis-
platin for 2, 4, 8 and 12 hours, respectively, prior to add-
ing 10 nM KB9520, was also investigated (Figure 4B). In
contrast to pre-treatment with KB9520 before adding
cisplatin, pre-treatment with cisplatin prior to KB9520
addition did not result in synergistic inhibition of cell
growth and viability.Figure 4 KB9520 pre-treatment synergizes with cisplatin. A) Effect of a
(10 nM) treatment on REN cell viability. B) Effect of adding KB9520 (10 nM)
cell viability. Each graph is representative of three independent experimentNext we explored the combination of 2 hours KB9520
pre-treatment with different concentrations of cisplatin
(range 20–100 μM) (Figure 5A). The most efficacious
anti-proliferative effect was observed when KB9520 pre-
treatment was combined with the highest concentration
of cisplatin (100 μM). Interestingly, 2 hours pre-treatment
with KB9520 in combination with 20 μM cisplatin was as
efficacious as 100 μM cisplatin alone.
Also the effect of combining KB9520 with pemetrexed
was explored in vitro (Figure 5B). Results of 2 hours
pre-treatment with 10 nM KB9520, wash-off and then
continued growth in normal medium, or medium sup-
plemented with pemetrexed at different concentrations
(range 5–22 μM) for an additional 24 hours are shown.dding of cisplatin (100 μM) 2, 4, 8 or 12 hours after start of KB9520
2, 4, 8 or 12 hours after start of cisplatin treatment (100 μM) on REN
s. Each point represents mean ± s.d. *p≤ 0.05.
Figure 5 (See legend on next page.)
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Figure 5 KB9520 sensitizes REN cells to cisplatin and the standard of care chemo combination. Effect on REN cell viability after 2 hours
pre-treatment with KB9520 (10nM) followed by wash-off and continued growth in normal medium supplemented with different concentrations
of A) cisplatin (20–100 μM), for additional 24 hours, B) pemetrexed (5–22 μM), for additional 24 hours and C) cisplatin (100 μM) or the cisplatin
(100 μM)/pemetrexed (22 μM) combination, for an additional 24 hours. Each graph is representative of three independent experiments. Each
point represents mean ± s.d. *p≤ 0.05.
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KB9520 in combination with pemetrexed compared to
KB9520 or pemetrexed alone. Finally, the effect of pre-
treating REN cells with 10 nM KB9520 for 2 hours prior
to adding the cisplatin/pemetrexed chemo combination
was explored in vitro (Figure 5C). As shown, adding cis-
platin or the cisplatin/pemetrexed combination to REN
cells pre-treated for 2 hours with KB9520 resulted in a
strong synergistic inhibitory effect on REN cell growth
and viability.
In summary, our data suggest that KB9520 acts as a che-
mosensitizer through ERβ, increasing the anti-tumorigenic
efficacy of cisplatin or the cisplatin/pemetrexed combin-
ation on malignant mesothelioma.
Mechanism of KB9520 sensitization to cisplatin cytotoxicity
REN cells were treated for 24 hours with 100 μM cisplatin
or pre-treated 2 hours with 10 nM KB9520 followed by
wash-off and continued growth in normal medium ±
100 μM cisplatin, for additional 24 hours. After treat-
ments, cells were stained with propidium iodide and an-
alyzed for cellular DNA content by flow cytometry. Pre-
treatment with KB9520 for 2 hours followed by 24 hours
cisplatin treatment resulted in significant and efficient
block in the G0/G1 phase and inhibition of cells enter-
ing the S-phase of the cell cycle compared to any other
treatment (data reported in Table 2 represent mean ± s.
d. (n = 3) of the percentage of cells in each phase of the
cell cycle). Moreover, a significant higher percentage of
dead cells were found in wells pre-treated with KB9520
followed by cisplatin compared to other treatment regi-
mens. A plausible explanation for the higher number of
dead cells in the KB9520/cisplatin treated cells was in-
duction of apoptosis. As expected from the cell cycle
analysis and percentage of dead cells, 2 hours KB9520
treatment, prior to addition of cisplatin, had the greatest
effect on the appearance of cleaved PARP1 (Figure 6A).
Interestingly, neither cisplatin nor KB9520 alone re-
sulted in significant PARP1 cleavage. As increased AKTTable 2 Cell cycle analysis of REN cells
Treatment/cell cycle phase Go/G1
Control 39 ± 1,9
100 μM cisplatin (24 hrs) 39 ± 0,9
10 nM KB9520 (2 hrs) + normal medium (24 hrs) 36 ± 1,9
10 nM KB9520 (2 hrs) + 100 μM cisplatin (24 hrs) 48 ± 0,8activity has been implicated in the control of prolifera-
tion, apoptosis and cisplatin resistance [44], we analyzed
its activation status following different treatments. As
shown in Figure 6A, KB9520 treatment significantly re-
duced AKT phosphorylation both in the absence and in
the presence of cisplatin. The mechanism for the com-
bined effect of KB9520 and cisplatin on AKT pathway
modulation, PARP1 cleavage and increased cell death
needs further studies.
KB9520 pre-treatment protects MET5A cells to cisplatin
cytotoxicity
Cisplatin is widely used in the treatment of various hu-
man solid tumors, but it is also associated with signifi-
cant toxicity. We therefore tested the effect of KB9520
on cisplatin toxicity in the normal mesothelium derived
cell line MET5A (Figure 6B, C). MET5A cells showed
higher sensitivity to cisplatin treatment than REN cells,
with an IC50 of 25 μM (Figure 6B). As previously de-
scribed for REN cells, we treated MET5A cells with 10
nM KB9520 for 2 hours followed by wash-off and incu-
bation in normal medium alone or in the presence of
three concentrations of cisplatin (25, 50, 100 μM) for
additional 24 hours. As reported in Figure 6B, KB9520
alone had no effect on MET5A cell proliferation or viabil-
ity, while a protective effect was observed when KB9520
pre-treatment was combined with low concentrations of
cisplatin. As previously described for REN cells, we ana-
lyzed PARP1 cleavage as an indicator of cell death.
Western-blot analysis (Figure 6C) revealed that KB9520
pre-treatment reduced the percentage of cleaved PARP1
in cells exposed to all concentrations of cisplatin, in
accordance with data obtained on cell viability. Regarding
phosphorylated AKT, KB9520 had no effect on basal
pAKT levels in the MET5A control cells but it antagonized
the cisplatin-mediated inhibition of AKT activation
(Figure 6C). AKT pathway activation is associated with
anti-apoptotic effects and cell survival and together
with the effects of KB9520 on reduced PARP1 cleavage,S G2/M Dead cells (sub G1)
33 ± 2,4 25 ± 0,5 3 ± 1
30 ± 2,3 23 ± 3,2 8 ± 2
29 ± 0,9 27 ± 0,9 8 ± 2
2 ± 2 28 ± 2,9 22 ± 1
Figure 6 Mechanism of KB9520 sensitization to cisplatin cytotoxicity. A) Western blot analysis and relative densitometry of PARP1 cleavage
and AKT phosphorylation in REN cells treated for 24 hours with cisplatin (25, 50 and 100 μM) or pre-treated 2 hours with KB9520 (10 nM) followed
by wash-off and continued growth in normal medium ± cisplatin (25, 50 and 100 μM), for additional 24 hours. Total AKT and Tubulin staining
were used for normalization. B) Effect on MET5A cell viability after 24 hours treatment with cisplatin (25, 50 and 100 μM) or 2 hours pre-treatment
with KB9520 (10 nM) followed by wash-off and continued growth in normal medium ± different concentrations of cisplatin (25, 50 and 100 μM),
for additional 24 hours. Each point represents mean ± s.d. *p≤ 0.05. C) Western blot analysis and relative densitometry of PARP1 cleavage and
AKT phosphorylation in MET5A cells treated with cisplatin (25, 50 and 100 μM) for 24 hours or pre-treated for 2 hours with KB9520 (10 nM)
followed by wash-off and continued growth in normal medium ± different concentrations of cisplatin (25, 50 and 100 μM), for additional 24 hours.
Total AKT and Tubulin staining were used for normalization. Data are representative of three separate experiments.
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platin cytotoxicity in the non-malignant MET5A cells.
Discussion
MPM is typically refractory to current treatment options
using chemotherapy. In a first line setting, pemetrexed
in combination with cisplatin has been accepted as an
almost universal standard. In the second line setting,
various chemotherapy agents have been used, either as
monotherapy or as part of polytherapy, but none has
been successfully validated.
A recently published review, based on results of a
meta-analysis of unresectable MPM, suggests that response
rate and survival are greater for combination therapy than
for single-agent regimens, and that platinum-containing
regimens have greater efficacy than non-platinum-con-
taining combinations, confirming that platinum-basedchemotherapy remains the most effective treatment for
patients with MPM [45].
Our group has recently demonstrated that ERβ exerts
a key role as a tumor-suppressor gene in MPM [13,15]
and its activation may also explain the gender difference
clinically observed for the prognosis of MPM.
In this study we report that activating ERβ with the
highly selective ligand KB9520 resulted in a concentra-
tion and time-dependent inhibition of REN malignant
mesothelioma cell growth in vitro. Both KB9520 and E2
displayed bell-shaped responses with growth inhibition
at low doses and opposite effect at high doses. Bell-shaped
responses to hormones are not unusual phenomena;
“hormesis” is a biphasic dose response phenomenon char-
acterized by a low dose stressful stimulation and a high
dose adaptive response (inhibition) that increases the re-
sistance of the cell to evoked stress [46,47]. Both ER
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which may explain the observed biphasic responses of
KB9520 and E2. Other plausible explanation could be the
cyclic on/off process of ER on promoters [48,49] leading
to degradation of the ERβ protein.
Although KB9520 and E2 had similar growth inhibitory
effect on the REN cells there was a difference in time to
maximal effect, 24 hours for KB9520 and 72 hours for E2.
This time to effect difference between KB9520 and E2
may depend on the different ERβ conformational change/
s induced by KB9520 and E2, respectively, which in turn
may have an effect on co-regulatory protein interactions
including type of co-regulatory complex, stoichiometry
and kinetics.
Evaluation of the anti-proliferative effect of KB9520 on
a collection of human malignant mesothelioma cell lines
showed a strict dependence on ERβ expression and that
the growth inhibitory efficacy was related to the level of
ERβ expressed. Lack of anti-proliferative effect of KB9520
in the ERβ positive non-malignant mesothelium derived
MET5A cells is difficult to understand and needs further
investigation. However, the difference in the regulatory
mechanisms/signaling pathways for cell growth, survival
and metabolism between non-malignant and malignant
cells may somehow influence the activity of ERβ and its
susceptibility to respond to an ERβ agonist. Differences in
post-translational modification/s of ERβ and/or cell
compartment localization are plausible explanations for
activity or no activity of ERβ in malignant compared to
non-malignant cells. Of note though, the non-malignant
MET5A cells did respond to KB9520 when stressed by
cisplatin.
The enhanced growth inhibitory effect of cisplatin/
pemetrexed in combination with KB9520 in REN cells
in vitro translated to synergistic anti-tumorigenic activity
in vivo. Treatment with KB9520 in combination with
cisplatin/pemetrexed in vivo had greater efficacy than ei-
ther treatment alone and caused a significantly reduced
tumor load compared to vehicle treated animals at the
end of the treatment period. Moreover, the triple combin-
ation shrunk the tumor volume even below the tumor vol-
ume at the start of treatment.
Also in a second human malignant mesothelioma cell
line, MMP [13], KB9520 in complex with cisplatin resulted
in synergistic growth inhibition compared to KB9520 or
cisplatin alone in vitro (data not shown). Moreover, similar
to the effect in REN cells, the combination of KB9520 and
cisplatin in the MMP cells decreased the level of phos-
phorylated AKT and increased the levels of cleaved PARP1
(data not shown).
That a brief exposure of malignant mesothelioma cells
to KB9520 (2 hours) elicited a stronger growth inhibitory
effect in vitro compared to continuous exposure is suggest-
ive of a hit-and-run mechanism. The long-lived biologicalactivity of KB9520 (≥24 hours) together with a hit-and-
run type of mechanism adds to our understanding of
the in vivo tumor inhibitory efficacy of KB9520 despite its
short plasma half-life of approximately 1 hour in mice.
The PI3K/AKT signaling pathway is aberrantly active
and plays a critical role in cell cycle progression and cell
survival in human MPM including the sensitivity to cis-
platin [50]. We have previously demonstrated a role of
AKT activation in MPM cell response to cisplatin [44].
Here we show that KB9520 significantly reduced pAKT
levels both in vitro and in vivo (data not shown), which,
at least in part, may explain the observed sensitization to
cisplatin cytotoxicity. The observed reduction in AKT
phosphorylation warrant further investigation; it could
be due to either modulation of the rate of both protein kin-
ase and phosphatase activities or to AKT post-translational
modification that could affect its localization and/or activa-
tion status.
The order of drug administration may sometimes be
very important for optimal therapeutic efficacy [51,52].
Exposure of REN cells to KB9520 prior to cisplatin re-
sulted in synergistic inhibition of malignant mesotheli-
oma cell proliferation and survival whereas the reverse
order of drug exposure did not even result in additive ef-
ficacy. Furthermore, KB9520 preconditioned malignant
mesothelioma cells to low-concentration cisplatin cyto-
toxicity; combination of KB9520 with 20 μM cisplatin
was as efficacious as 100 μM cisplatin alone. Thus, these
data imply that KB9520, through ERβ, acts as a chemo-
sensitizer increasing cisplatin cytotoxicity in human ma-
lignant mesothelioma cells.
Chemotherapy and in particular cisplatin is widely
used in the treatment of various human solid tumors.
However, cisplatin is associated with serious toxicity, which
limits its use; the majority of patients diagnosed with MPM
are older than 65 years and their health condition may
therefore not allow the standard chemo dosing regimen of
cisplatin/pemetrexed. To investigate the cytotoxic effect of
the cisplatin/KB9520 combination in non-malignant meso-
thelial cells we treated the mesothelium-derived MET5A
cells with various concentrations of cisplatin in the pres-
ence or absence of KB9520. In contrast to the effect in the
malignant REN cells KB9520 diminished the toxicity of cis-
platin in the MET5A cells, in part explained by the reduced
PARP1 cleavage and increased pAKT levels. It has been de-
scribed that ER can increase PI3K/AKT activity by inter-
action with the p85 subunit of PI3K [53,54]. However, if
that explains the increased pAKT levels in the MET5A
cells needs to be explored in more detail.
Conclusions
In summary, in this report we have shown that MPM
cell proliferation and tumor growth can be effectively
suppressed by selective agonist activation of ERβ. We
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through activation of ERβ and that the order of drug ad-
ministration in combination with cisplatin/pemetrexed is
essential for the synergistic efficacy observed in vitro
and in vivo. KB9520 had no cytotoxic effect in the ERβ
expressing non-malignant mesothelium derived MET5A
cells. In contrast, it diminished cisplatin cytotoxicity in
these cells. Thus, combination of KB9520 with SOC (cis-
platin/pemetrexed combination) may increase the sensi-
tivity of MPM tumors to the SOC regimen in patients and
perhaps result in higher response rates, extended progres-
sion free survival (PFS) and prolonged overall survival
(OS), without adding toxicity. Furthermore, combination
with KB9520 may allow milder SOC (cisplatin) regimen
without loss of anti-tumor efficacy and thereby may be-
come an option for patients that cannot tolerate the




The monoclonal antibodies specific for α-Tubulin,
PARP1 and the polyclonal antibody specific for ERβ
were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Phospho-AKT (pSer473) was from Cell
Signaling Technology (Beverly, MA, USA), anti-mouse
and anti-rabbit IgG peroxidase conjugated antibodies
and chemical reagents were from Sigma-Aldrich (St Louis,
MO, USA). ECL was from Amersham Pharmacia Biotech
(Uppsala, Sweden). Nitrocellulose membranes and protein
assay kit were from Bio-Rad (Hercules, CA, USA). Culture
media, sera, antibiotics and LipofectAMINE transfection
reagent were from Invitrogen (Carlsbad, CA, USA). The
ERβ selective agonist KB9520 (see Additional file 1:
Figure S1) was designed and synthesized by Karo Bio
(Huddinge, Sweden). (KB9520 has been described previ-
ously [36,41-43]. The compound can be obtained follow-
ing contact with Karo Bio AB [stefan.nilsson@karobio.se]
and after signing of a Material Transfer Agreement to-
gether with a detailed protocol of planned study. A fee
covering the cost of compound synthesis will be charged).
Cell cultures and transfection
The epithelioid MPM derived REN cell line, used as the
principal experimental model in this investigation, was
isolated, characterized and kindly provided by Dr. Albelda
S.M. (University of Pennsylvania, Philadelphia; PA, USA).
Cells were characterized by BMR Genomics s.r.l. using the
PowerPlex 18D System kit. The biphasic MSTO-211H
and the mesothelial MET5A cell lines were obtained from
the Istituto Scientifico Tumori (IST) Cell-bank, Genoa,
Italy; the MMB cell line derived from pleural effusions of
patients with MPM and stabilized in culture [55]; the
H2596 cell line produced by Dr. H. I. Pass from surgicalspecimens derived from patients with resected MPM [56]
were kindly provided by Dr. W. Thomas (RCSI, Dublin,
IRL) in 2011. Cells were grown in RPMI medium supple-
mented with 10% FBS, 100 μg/ml streptomycin and
10 μg/ml penicillin at 37°C in a humidified environment
containing 5% CO2. Mycoplasma infection was excluded
by the use of Mycoplasma PlusTM PCR Primer Set kit
from Stratagene (La Jolla, CA, USA). Cells grown to 80%
confluence in tissue culture dishes were transiently trans-
fected with the pCNX2 plasmid expressing human wild
type ERβ (Addgene, Cambridge, MA, USA) using Lipofec-
tAMINE reagent as described by the manufacturer.
Gene silencing was achieved using an ERβ-specific
shRNA lentiviral plasmid (pLKO.1-puro) by Sigma (St
Louis, MO, USA) or specific siRNAs by Qiagen (Hilden,
Germany).
Proliferation assays
Cells were seeded at a density of 10×104 cells/well in 6-
well plates in RPMI medium supplemented with 10%
FBS, 100 μg/ml streptomycin and 10 μg/ml penicillin
and incubated over-night at 37°C in a humidified envir-
onment containing 5% CO2 to allow adherence. Follow-
ing treatment cells were trypsinized and stained with
Trypan blue. The number of cells considered viable (un-
stained cells) was counted in a Bürker haemocytometer
within 5 minutes after staining.
Wash-off experiments
Cell cultures were pretreated with KB9520 for 1–16
hours (depending on experiment) followed by wash-off
and then replenished with normal growth medium ± cis-
platin, pemetrexed or cisplatin/pemetrexed. Total incuba-
tion time was 24–72 hours (depending on experiment).
Control cultures were maintained in normal growth
medium without added drug. The number of viable cells
was determined as described. For details of each experi-
ment see figure legends.
Add-on experiments
In the add-on experiments the second drug was added
directly to the cell culture medium without wash-off of
the first drug. Total incubation time was 24 hours. Con-
trol cultures were maintained in normal growth medium
without added drug. The number of viable cells was de-
termined as described.
Cell lysis and immunoblot
Cells were extracted with 1% NP-40 lysis buffer (1% NP-
40, 150 mM NaCl, 50 mM Tris–HCl pH 8.5 mM EDTA,
10 mM NaF, 10 mM Na4P2O7, 0.4 mM Na3VO4) with
freshly added protease inhibitors (10 μg/ml leupeptin,
4 μg/ml pepstatin and 0.1 Unit/ml aprotinin). Lysates
were centrifuged at 13.000 × g for 10 minutes at 4°C and
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Proteins were separated by SDS-PAGE under reducing
conditions. Following SDS-PAGE, proteins were trans-
ferred to nitrocellulose, reacted with specific antibodies
and then detected with peroxidase-conjugate secondary
antibodies and chemiluminescent ECL reagent. Densito-
metric analysis was performed using the GS 250 Mo-
lecular Image (Bio-Rad).
Cell cycle analysis
For cell cycle/apoptosis analysis, 5 × 105 cells were
seeded in tissue culture plates and treated with 10 nM
KB9520, 100 μM cisplatin or the combination of the two
drugs for 24 hours at 37°C in a 5% CO2 atmosphere.
After incubation, detached and suspended cells were
harvested in complete RPMI and centrifuged at 500 × g
for 10 minutes. Pellets were washed with PBS, fixed in
ice-cold 75% ethanol at 4°C, treated with 100 mg/mL
RNAse A for 1 hour at 37°C, stained with 25 μg/mL pro-
pidium iodide and finally analyzed by using a flow cyt-
ometer FACS (Becton Dickinson, San Jose, CA, USA)




CD1 nude mice (males, 6 weeks old; Charles River,
Calco, Italy) received intra-peritoneal (i.p.) injections of
2×106 luciferase transduced REN cells in 0.5 mL of
RPMI medium. After anesthetization and i.p. injections
of 0.3 mL of 15 mg/mL D-luciferin, tumor dimension
and localization of luminescent cells was monitored
using the In Vivo Imaging System (IVIS®) system 100
series (Xenogen Corporation, Hopkinton, MA, USA).
Regions of interest were identified around the tumor
sites and were quantified as total photon counts using
Living Image software (Xenogen Corporation). The values
of tumor sizes were obtained by subtracting luminescence
signals of each weekly measurement by the average of all
animals within a treatment group on the 15th day after in-
oculation (day when treatment started). To evaluate treat-
ment toxicity, mice were weighed at the start and end of
treatments. Mice were killed and necropsied after 20 days
of treatment. In vivo experiments were approved by Isti-
tuto Scientifico Tumori (Genoa, Italy) ethical committee
and conform to the relevant regulatory standards. Mice
were maintained and handled under aseptic conditions,
and were allowed access to food and water ad libitum.
Drug administration
An elapse of 15 days was allowed for the formation of
detectable tumor nodules, assessed by IVIS® imaging.
Mice were then weighed and stratified into treatmentgroups of ten animals. Treatment protocols were done
from the 15th day to the 35th day, and mice were ana-
lyzed weekly by IVIS® imaging to assess tumor growth.
One dose of KB9520 was used (10 mg/kg/day). KB9520
was dissolved in the vehicle (5% DMSO/40% PEG 400/
55% water) and administrated once daily (days 15–35)
by sub-cutaneous administration. 5 mg/kg cisplatin solu-
tion (Ebewe Italia srl, Roma, Italy) was administrated
subcutaneously at day 18 and 25, respectively, and
150 mg/kg pemetrexed (dissolved in isotonic saline) (Eli
Lilly, Houten, Nederland) was injected subcutaneously
at days 19–23 and 26–30, respectively. Untreated ani-
mals were dosed with empty vehicle. At day 35 mice
from the four groups were euthanized and necropsied.
Tumors growing in the peritoneum were excised, and
one part of the tumor tissues was immediately frozen
and stored at −80°C for subsequent analysis.Statistical analysis
Statistical evaluation of the differential analysis was per-
formed by one way ANOVA and Student’s t-test. The
threshold for statistical significance was set at p ≤ 0.05.
The statistical analysis of in vivo experiments was done
by using R [57]. To compare different groups we used
the non-parametric Kruskal-Wallis test; if differences
were found significant (p ≤ 0.05) we subsequently ap-
plied the Wilkoxon rank sum test to do the pair wise
comparisons. To compare tumor growth curves we used
the StatMod package.Additional file
Additional file 1: Figure S1. Concentration-dependent induction of
reporter gene expression in 293 cells genetically engineered to express
the human estrogen receptor alpha (hERα) and human estrogen receptor
beta 1 (hERβ) [58].
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